Serum amyloid A (SAA) proteins belong to a family of acute-phase reactants, playing an integral role in defending the organism from pathological damage. Despite a wealth of data on the regulation of SAA transcripts in teleosts, there is only limited information on these proteins' abundance in fish. The aim of this study is to characterise SAA protein levels in salmonids using a newly developed antibody specific to salmonid SAA. The salmonid SAA antibody detected SAA and accurately discriminated between stimulated and control specimens from rainbow trout macrophage cell line (RTS-11) in vitro, as well as rainbow trout challenged with - or flagellin-stimulated Atlantic salmon in vivo. The presence of SAA protein was analysed in RTS-11 cell line supernatants, liver, and spleen samples using ELISA, immunoblotting, and immunohistochemistry. This study is the first to characterise SAA protein levels in salmonids in vivo and in vitro. The newly developed salmonid SAA antibody was able to discriminate between stimulated and unstimulated specimens, showing that it can be used to study the acute-phase response in salmonids with the potential to be further developed into assays to monitor and evaluate health in wild and farmed fish.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453338 | PMC |
| http://dx.doi.org/10.3390/cells12162097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
School of Pharmacy, Chapman University, Irvine, CA, USA.
Background: Although novel treatments for Alzheimer's disease (AD) have begun to show modest therapeutic effects, agents that target hallmark AD pathology and offer neuroprotection are desired. Erythropoietin (EPO) is a glycoprotein hormone with neuroprotective effects but is faced with challenges including limited brain uptake and increased hematopoietic side effects with long-term dosing. Therefore, EPO has been modified and bound to a chimeric transferrin receptor monoclonal antibody (cTfRMAb); the latter shuttles EPO past the blood-brain barrier (BBB) into brain parenchyma and reduces its plasma exposure and potential for side effects.
View Article and Find Full Text PDFImpact of the menstrual cycle phases and time of day on markers of stress: salivary α-amylase and secretory immunoglobulin A.
Stress
December 2025
Metabolic & Applied Physiology Laboratory, Department of Health & Human Performance, Texas State University, San Marcos, TX, USA.
Article Synopsis
- The study investigates the effects of menstrual cycle phases and time of day on various stress and immune biomarkers, including salivary α-amylase (sAA) and secretory immunoglobulin A (SIgA), in a group of 17 participants.
- No significant interactions were found between menstrual cycle phases and time of day for the biomarkers, resting blood pressure, heart rate, or body composition.
- However, results indicate that resting heart rate and sAA levels were higher in the afternoon, while SIgA levels were higher in the morning, highlighting the influence of time of day on these markers, rather than the menstrual cycle phases.
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and associated with high response rates.
Blood Adv
December 2024
Universidade Federal de São Paulo, Brazil.
Immunosuppressive therapy (IST) using horse antithymocyte globulin (h-ATG) combined with cyclosporine (CsA) and eltrombopag is the standard care for aplastic anemia (AA) in patients without a suitable matched donor. However, in many countries, h-ATG use has been discontinued, leaving rabbit ATG (r-ATG), which has a lower response rates and poorer survival, as the only alternative. In previous studies, alemtuzumab (ALZ), a humanized monoclonal antibody targeting CD52, combined with CsA resulted in an adequate ORR in AA patients.
View Article and Find Full Text PDFAntiphospholipid Antibody Syndrome: Concurrent Retinal Vein Occlusion and Homonymous Hemianopia From Ischemic Stroke.
J Neuroophthalmol
December 2024
John Sealy School of Medicine (HJY), University of Texas Medical Branch, Galveston, Texas; Department of Ophthalmology and Visual Sciences (CK), University of Texas Medical Branch, Galveston, Texas; Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program (TAN, GD), Weill Cornell Medicine, New York, New York; Department of Ophthalmology (SAA, OAD, AGL), Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas; Department of Ophthalmology (SAA), The University of Jordan, Amman, Jordan; Department of Ophthalmology (OAD), Hashemite University, Amman, Jordan; Department of Ophthalmology (AGL), Cullen Eye Institute, Baylor College of Medicine, Houston, Texas; Departments of Ophthalmology, Neurology, and Neurosurgery (AGL), Weill Cornell Medicine, New York, New York; Department of Ophthalmology (AGL), University of Texas MD Anderson Cancer Center, Houston, Texas; Texas A&M College of Medicine (AGL), Bryan, Texas; and Department of Ophthalmology (AGL), The University of Iowa Hospitals and Clinics, Iowa City, Iowa.
The improvement of a refractory enterocutaneous fistula with colchicine in a patient with Crohn's disease who had an MEFV gene mutation.
Clin J Gastroenterol
November 2024
Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Chuo-Ku Sapporo, Hokkaido, S1W16060-8543, Japan.
Enterocutaneous fistulas (ECFs) occurring in the setting of Crohn's disease (CD) are difficult to cure with medical treatment alone and affects a patient's quality of life. A 39-year-old man was diagnosed with an ileocolitis-type CD in 2007. His inflammation was insufficiently controlled despite the administration of an anti-tumor necrosis factor-alpha antibody.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!